Women with endometriosis wait an average of a decade for a diagnosis, and once they have it, their treatment options look much the same as they did fifty years ago. Writing in the Boston Herald, Yale-trained scientist and Metri Bio CEO Ashley Abel argues that the path to better options runs through something the field has largely skipped: understanding the biology of the disease itself. Read the full piece here →

From the Boston Herald, by Ashley Abel:

"Until we understand the biology driving the disease, we're largely making educated guesses."

"Rather than assuming every woman has the same disease, we are trying to identify its biological subtypes so future interventions can target the right patients for the right reasons."

"Endometriosis is not simply a gynecologic disorder confined to the pelvis. The disease is increasingly associated with chronic inflammation, cardiovascular risk, autoimmune conditions, and changes in pain processing throughout the body."

"The one-in-seven women with endometriosis deserve better than educated guesswork. They deserve options designed around the biology of their disease."

Abel's piece in the Boston Herald is a compelling case for slowing down to do the foundational science right, so that the breakthroughs that follow can deliver real results.

‍